CA2393844A1 - Methodes et compositions destinees a la fabrication d'adenovirus incompetents pour la replication - Google Patents

Methodes et compositions destinees a la fabrication d'adenovirus incompetents pour la replication Download PDF

Info

Publication number
CA2393844A1
CA2393844A1 CA002393844A CA2393844A CA2393844A1 CA 2393844 A1 CA2393844 A1 CA 2393844A1 CA 002393844 A CA002393844 A CA 002393844A CA 2393844 A CA2393844 A CA 2393844A CA 2393844 A1 CA2393844 A1 CA 2393844A1
Authority
CA
Canada
Prior art keywords
virus
assay
replication
adenovirus
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002393844A
Other languages
English (en)
Inventor
Vaughn B. Himes
Siyamak Rasty
Richard W. Peluso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genovo Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2393844A1 publication Critical patent/CA2393844A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Abstract

La présente invention concerne des lignées cellulaires de complémentation destinées à la production de virus incompétents pour la réplication, réduisant sensiblement ou éliminant la présence de virus compétents pour la réplication. L'invention concerne également des méthodes de fabrication et d'utilisation de ces lignées cellulaires de complémentation, ainsi que des molécules d'acide nucléique, des polynucléotides, et des vecteurs destinés à la fabrication de lignées cellulaires. En particulier, la présente invention concerne des lignées cellulaires de complémentation destinées à la production d'adénovirus (Ad) incompétents pour la réplication, réduisant sensiblement ou éliminant la présence d'Ad compétents pour la réplication (RCA) et pouvant servir à la production massive de particules infectieuses d'adénovirus incompétents pour la réplication pouvant être utilisées dans le traitement de patients humains, dans la thérapie génique par exemple. La présente invention concerne également un dosage destiné à détecter la présence de particules de virus compétent pour la réplication, en particulier d'RCA, dans une population de particules infectieuses de virus incompétent pour la réplication, en particulier des particules d'adénovirus incompétent pour la réplication, utilisant un dosage par ACP quantitative en temps réel avec un niveau de sensibilité permettant de détecter une particule de virus compétent pour la réplication parmi >= 10?9¿ particules de virus incompétent pour la réplication.
CA002393844A 1999-12-14 2000-12-07 Methodes et compositions destinees a la fabrication d'adenovirus incompetents pour la replication Abandoned CA2393844A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17055099P 1999-12-14 1999-12-14
US60/170,550 1999-12-14
US19626600P 2000-04-11 2000-04-11
US60/196,266 2000-04-11
PCT/US2000/033123 WO2001044280A2 (fr) 1999-12-14 2000-12-07 Methodes et compositions destinees a la fabrication d'adenovirus incompetents pour la replication

Publications (1)

Publication Number Publication Date
CA2393844A1 true CA2393844A1 (fr) 2001-06-21

Family

ID=26866208

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002393844A Abandoned CA2393844A1 (fr) 1999-12-14 2000-12-07 Methodes et compositions destinees a la fabrication d'adenovirus incompetents pour la replication

Country Status (5)

Country Link
EP (1) EP1238091A2 (fr)
JP (1) JP2003516743A (fr)
AU (1) AU1817401A (fr)
CA (1) CA2393844A1 (fr)
WO (1) WO2001044280A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677156B2 (en) 2001-07-23 2004-01-13 Genvec, Inc. Non-adenoviral gene product-based complementing cells for adenoviral vectors
EP1327688A1 (fr) * 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses avec capacité lytique augmentée
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
WO2004057035A2 (fr) * 2002-12-20 2004-07-08 Qbiogene Inc. Procede et necessaire de detection d'adenovirus replicalbes
WO2009006300A2 (fr) * 2007-06-28 2009-01-08 Advantagene, Inc. Production de lignées cellulaires pour la fabrication d'adénovirus
US8346485B2 (en) 2008-11-25 2013-01-01 Quest Diagnostics Investments Incorporated Methods and apparatuses for estimating initial target nucleic acid concentration in a sample by modeling background signal and cycle-dependent amplification efficiency of a polymerase chain reaction
CA3103367A1 (fr) * 2018-06-13 2019-12-19 The Council Of The Queensland Institute Of Medical Research Dosage de detection virale
US20190292609A1 (en) * 2019-05-30 2019-09-26 Trizell Ltd. Gene Therapy Vector Contamination Assay
WO2023039243A2 (fr) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Compositions antivirus de l'hépatite b (anti-vhb) et leurs méthodes d'utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925517A (en) * 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
ATE545711T1 (de) * 1993-11-12 2012-03-15 Phri Properties Inc Hybridisierungssonden zur nukleinsäuredetektion sowie universelle stämme, verfahren und kits
SI0833934T2 (sl) * 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
AU7665396A (en) * 1995-10-27 1997-05-15 Trustees Of The University Of Pennsylvania, The Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
EP1471146B1 (fr) * 1996-09-25 2009-01-07 Novartis AG Lignées cellulaires d'encapsidation permettant de faciliter le développement de vecteurs adénoviraux de grande capacité
US5994132A (en) * 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors

Also Published As

Publication number Publication date
WO2001044280A2 (fr) 2001-06-21
EP1238091A2 (fr) 2002-09-11
WO2001044280A3 (fr) 2001-11-29
JP2003516743A (ja) 2003-05-20
AU1817401A (en) 2001-06-25

Similar Documents

Publication Publication Date Title
AU717253B2 (en) Cells for the production of recombinant adenoviruses
US5824544A (en) Adenovirus vectors for gene therapy
KR100424803B1 (ko) 생존성오염입자-비함유아데노바이러스,이의제조방법및용도
AU711366B2 (en) Complementary adenoviral vector systems and cell lines
EP1226264B1 (fr) Lignees de cellules et produits d'assemblage servant a l'obtention d'adenovirus a deletion e-1 en l'absence d'adenovirus a capacite de replication
US6265212B1 (en) Packaging systems for human recombinant adenovirus to be used in gene therapy
NO321309B1 (no) Defektive, rekombinante adenovirus, cellelinje, samt et farmasoytisk preparat.
SK156799A3 (en) Method for the production of non-group c adenoviral vectors
CA2393844A1 (fr) Methodes et compositions destinees a la fabrication d'adenovirus incompetents pour la replication
WO1996030534A1 (fr) Vecteurs d'adenovirus pour therapie genique
KR100484441B1 (ko) IVa2유전자가불활성화된결손재조합아데노바이러스
CN117545842A (zh) SMN1和miR-23a在治疗脊髓性肌萎缩中的协同效应
WO2006033999A2 (fr) Adenovirus contenant une proteine de remplacement de fibre
Wang et al. Episomal segregation of the adenovirus enhancer sequence by conditional genome rearrangement abrogates late viral gene expression
CA2373352A1 (fr) Vecteurs adenoviraux de traitement de maladies
AU772544B2 (en) E1B-deleted adenoviral shuttle vectors
US6764674B1 (en) Adenovirus E1B shuttle vectors
AU752811B2 (en) Preparation of recombinant adenovirus carrying a rep gene of Adeno-Associated Virus
AU703768B2 (en) Complementary adenoviral vector systems and cell lines
AU2005209653A1 (en) Adenoviral vectors for treating disease
WO2008112540A2 (fr) Cellules pour la production de protéines et de vecteurs adénoviraux

Legal Events

Date Code Title Description
FZDE Discontinued